FDA Approves Pertuzumab for Neoadjuvant HER2-positive Breast Cancer
The U.S. Food and Drug Administration (FDA) today granted pertuzumab (Perjeta) accelerated approval for the treatment of patients with HER2-positive early stage breast cancer prior to surgery who are at high risk for recurrence or metastasis.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Food and Drug Administration (FDA) | HER2 | Neoadjuvant Therapy